Goldman Sachs’s Purple Biotech PPBT Stock Holding History

Goldman Sachs’s Portfolio PPBT Stock Details PPBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-131	Closed	-$100K	–	6287
2020 Q4	$100K	Buy	131 +74	+130%	+$62.4K	﹤0.01%	5289
2020 Q3	$50K	Buy	+57	New	+$70.4K	﹤0.01%	5192

Other funds holding PPBT

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WTB

Washington Trust Bank Spokane, Washington $1.36B AUM 21.14% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Goldman Sachs's PPBT Position: Q1 2021 in Review

Goldman Sachs sold out of Purple Biotech (PPBT) in Q1 2021, closing a stake of 131 shares — an estimated $100K sold.

Goldman Sachs first reported a position in PPBT in Q3 2020 and held it in 2 quarters. The position peaked at $100K in Q4 2020. 15 funds tracked by Wall St. Rank hold PPBT as of Q1 2021.

Goldman Sachs reported no remaining Purple Biotech position as of Q1 2021 after selling out during the quarter.
Goldman Sachs sold 131 Purple Biotech shares in Q1 2021, an estimated $100K.
Goldman Sachs first reported a position in Purple Biotech in Q3 2020 and held it in 2 quarters.
Goldman Sachs's Purple Biotech position peaked at $100K in Q4 2020.
15 funds tracked by Wall St. Rank held Purple Biotech as of Q1 2021.

Based on Goldman Sachs's 13F filing for Q1 2021, filed 17 May 2021.